From: HPV-specific risk assessment of cervical cytological abnormalities
normal | AGC | ASC-H | ASC-US | LSIL | HSIL | SCC | ||
---|---|---|---|---|---|---|---|---|
HPV status | N | 1745 (78.5%) | 8 (0.4%) | 26 (1.2%) | 264 (11.9%) | 152 (6.8%) | 23 (1.0%) | 6 (0.3%) |
Age | 37.9 ± 9.1 | 39.4 ± 14.5 | 40.1 ± 9.1 | 35.0 ± 9.2 | 36.6 ± 9.4 | 41.1 ± 7.8 | 44.8 ± 14.2 | |
HPV infection | 359 (20.6%) | 3 (37.5%) | 19 (73.1%) | 159 (60.2%) | 127 (83.6%) | 17 (73.9%) | 4 (66.7%) | |
HR-HPV infection | 318 (18.2%) | 3 (37.5%) | 19 (73.1%) | 140 (53.0%) | 119 (78.3%) | 16 (69.6%) | 4 (66.7%) | |
LR-HPV infection | 60 (3.4%) | 0 (0.0%) | 3 (11.5%) | 33 (12.5%) | 15 (9.9%) | 1 (4.3%) | 0 (0.0%) | |
HR + LR infection | 19 (1.1%) | 0 (0.0%) | 3 (11.5%) | 14 (5.3%) | 7 (4.6%) | 0 (0.0%) | 0 (0.0%) | |
Multiple HR-HPV infection | 57 (3.3%) | 0 (0.0%) | 1 (3.8%) | 33 (12.5%) | 42 (27.6%) | 2 (8.7%) | 0 (0.0%) | |
Symptoms | Post-coital bleeding | 238 (13.6%) | 1 (12.5%) | 5 (19.2%) | 37 (14.0%) | 30 (19.7%) | 1 (4.3%) | 1 (16.7%) |
Postmenopausal bleeding | 493 (28.3%) | 2 (25.0%) | 3 (11.5%) | 87 (33.0%) | 51 (33.6%) | 5 (21.7%) | 2 (33.3%) | |
Last Abnormal LCT | 136 (7.8%) | 2 (25.0%) | 1 (3.8%) | 29 (11.0%) | 10 (6.6%) | 0 (0.0%) | 0 (0.0%) | |
Abnormal menstruation | 444 (25.4%) | 1 (12.5%) | 7 (26.9%) | 67 (25.4%) | 41 (27.0%) | 7 (30.4%) | 1 (16.7%) | |
Irregular bleeding | 72 (4.1%) | 0 (0.0%) | 1 (3.8%) | 10 (3.8%) | 9 (5.9%) | 0 (0.0%) | 0 (0.0%) | |
Uterine prolapse | 158 (9.1%) | 1 (12.5%) | 3 (11.5%) | 26 (9.8%) | 12 (7.9%) | 5 (21.7%) | 0 (0.0%) | |
Others | 589 (33.8%) | 3 (37.5%) | 13 (50.0%) | 82 (31.1%) | 42 (27.6%) | 10 (43.5%) | 2 (33.3%) |